INTRODUCTION
============

Venous malformations (VMs) are slow flow developmental anomalies of the veins which do not proliferate and normally do not involute \[[@b1-neuroint-2019-00213]-[@b37-neuroint-2019-00213]\]. These lesions can develop anywhere in the body, including structures of the face, head and neck. Due to the delicate interplay between aesthetics, function, and anatomy in this region, management of these lesions with any treatment modality can be challenging.

Over the past several decades, sclerotherapy with various agents has been demonstrated to be effective for face, head and neck VMs \[[@b1-neuroint-2019-00213],[@b6-neuroint-2019-00213],[@b13-neuroint-2019-00213],[@b38-neuroint-2019-00213]-[@b40-neuroint-2019-00213]\]. However, the evidence for treatment of these lesions is often based off of smaller case series which makes generalizing results to the greater population difficult. Furthermore, comparative studies examining the efficacy and safety of various sclerotherapy agents are few and far between. The goals of this systematic review and meta-analysis were to 1) understand the overall safety and efficacy rates of percutaneous sclerotherapy for treatment of VMs in the face, head and neck and 2) compare safety and efficacy rates of commonly used sclerotherapy agents. It is our hope that data from this study could be used to better inform providers and patients regarding the benefits and risks of percutaneous sclerotherapy for treatment of face, head and neck VMs.

MATERIALS AND METHODS
=====================

Literature search
-----------------

The systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines \[[@b37-neuroint-2019-00213]\]. A comprehensive literature search of the databases PubMed, Ovid MEDLINE, and Ovid EMBASE was designed and conducted by an experienced librarian with input from the authors. The search duration was 2 months. The key words "sclerotherapy," "vascular malformations," "venous malformations," "arteriovenous malformation," "hemangioma," "lymphatic malformation, "head," "neck," "facial," "oropharyngeal," and "orbital" were used in "AND" and "OR" combinations. The search was limited to articles published from 2000 to 2018. Inclusion criteria were the following: 1) English or Italian language, 2) case series reporting greater than 5 patients, 3) studies reporting image guided percutaneous sclerotherapy, 4) studies reporting exclusively face, head and neck VMs or subdividing outcomes and complications by anatomical region, and 5) studies classifying VMs appropriately using the International Society for the Study of Vascular Anomalies. Exclusion criteria were: 1) case series reporting fewer than 5 patients, 2) case reports, 3) vascular malformation not of the head and/or neck region (e.g., sclerotherapy for varicose veins in legs), and 4) studies not classifying lesions according to the International Society for the Study of Vascular Anomalies criteria. International Society for the Study of Vascular Anomalies criteria on imaging and clinical exam for VMs on imaging include 1) septated lobulated T2 hyperintense and T1 hypointense mass without mass effect, 2) phleboliths which are characteristically hypointense on T1/T2, 3) presence of fluid-fluid levels, 4) no flow voids on spin echo sequences, 5) the lesion infiltrates tissue planes, 6) no arterial or early venous enhancement, and 7) diffuse enhancement on delayed images.41 On clinical exam, VMs appear as faint blue, soft and easily compressible non-pulsatile masses. The lesions characteristically enlarged with Valsalva maneuver and in dependent positions and decompress with local compression.

In studies with overlapping patient populations written by the same author/institution, we only included the largest or most complete dataset. In cases where outcomes were separated out by the type of sclerotherapy agent used, we abstracted outcomes separately for each agent in order to perform our subgroup analyses. Two authors determined inclusion and exclusion criteria for the studies in the literature search with differences resolved by the senior author.

Outcomes and data extraction
----------------------------

For each study, we extracted the following baseline information: number of patients, mean or median age and gender, number of malformations treated, location of malformations, sclerosing agent and its mean volume used, mean number of treatment sessions, and mean length of radiographic and clinical follow-up. The primary outcome of this study is the efficacy of sclerotherapy which includes complete cure of the vascular malformation (resolution of the VM on physical exam), partial cure of the vascular malformation (partial decrease in VM size), lack of benefit following sclerotherapy, improvement in quality of life (QoL), and patient satisfaction. Secondary outcomes are adverse events after sclerotherapy, including respiratory complications, skin necrosis/scars, any permanent morbidity/mortality, local temporary complications). Permanent morbidity and mortality were defined as mortality or any permanent neurological deficit. Local temporary complications included erythema, swelling, and pain.

For our subgroup analysis by sclerotherapy agent, we separated outcomes by agent. We were able to abstract data for the following individual agents: bleomycin, ethanol, sodium tetradecyl sulfate (STS), ethanolamine and pingamycin.

Study risk of bias
------------------

We modified the Newcastle-Ottawa Quality Assessment Scale to assess the methodologic quality of the studies included in this meta-analysis. This tool is designed for use in comparative studies; however, because the studies did not include a control group, we assessed study risk of bias based on selected items from the tool, focusing on the following questions: 1) Did the study include all patients or consecutive patients versus a selected sample?, 2) Was the study retrospective or prospective?, 3) Was clinical follow-up satisfactory, thus allowing ascertainment of all outcomes?, 4) Were outcomes clearly reported?, and 5) Were there clearly defined inclusion and exclusion criteria?

Statistical analysis
--------------------

We estimated from each cohort the cumulative prevalence and 95% confidence interval (CI) for each outcome. Event rates were pooled across studies with a random-effects meta-analysis. Heterogeneity across studies was evaluated using the I^2^ statistic. An I^2^ value of \>50% suggests substantial heterogeneity. We also extracted a 2×2 table to calculate P values for the comparisons among the results. For the purpose of statistical comparisons we chose bleomycin sclerotherapy as the reference group, since it is the sclerosing agent most commonly used in the USA. Meta-regression was not used in this study. Statistical analyses were performed using OpenMeta\[Analyst\] (<http://www.cebm.brown.edu/openmeta/>; Biostat, Englewood, NJ, USA).

RESULTS
=======

Literature search
-----------------

The initial literature search yielded 1,211 articles. On review of the abstracts and titles, we excluded 1,126 articles. Eightyfive articles were selected for full-text screening, of which 37 met inclusion criteria \[[@b1-neuroint-2019-00213]-[@b37-neuroint-2019-00213]\]. The remaining 48 articles were excluded for reasons including 1) failure to separate outcomes by anatomic location (9 articles), 2) inclusion of lymphatic or venolymphatic malformations rather than pure VMs (14 articles), 3) use of confusing or unclear terminology making it difficult to ascertain whether lesions were VMs or hemangiomas (12 articles), and 4) mixture of VMs, AVMs and lymphatic malformations (13 articles). All studies included in the analysis had at least one or more outcome measure available for one or more of the patients groups analyzed. [Fig. 1](#f1-neuroint-2019-00213){ref-type="fig"} shows the flow chart according to the PRISMA statement \[[@b37-neuroint-2019-00213]\].

These 37 studies included a total of 2,067 patients. The smallest study included 10 patients and the largest included 358 patients. Mean age was 24.9 years. There was a female predilection (1:1.2). The mean number of malformations per patient was 1.08 and they were all located in the head and/or neck region. The highest number of treated malformations per study was 358, while the least was 10. The mean number of treatment sessions per patient was 2.4. The mean length of radiographic and clinical follow-up from the time of the first treatment was 16.61 months and 18.04 months respectively.

Most included studies used a single sclerosing agent for each vascular malformation, while the remainder used a combination of them. Five studies reported outcomes of bleomycin sclerotherapy, 10 studies reported outcomes of ethanol sclerotherapy, 7 studies reported outcomes of STS sclerotherapy, 4 studies reported outcomes of ethanolamine sclerotherapy, and 4 studies reported outcomes of pingamycin sclerotherapy. In 11 studies either multiple agents were used and we could not separate outcomes by agent or other sclerosing agent including OK-432 were used. A summary of included studies is provided in [Table 1](#t1-neuroint-2019-00213){ref-type="table"}.

Efficacy outcomes
-----------------

Overall complete cure rates were reported in 1,736 patients. The overall rate of complete cure following percutaneous sclerotherapy with any agent was 64.7% (95% CI, 57.4--72.0%). STS had the lowest complete cure rate at 55.5% (95% CI, 36.1--74.9%) while pingyangmycin had the highest cure rate at 82.9% (95% CI, 71.1--94.7%). [Fig. 2](#f2-neuroint-2019-00213){ref-type="fig"} shows the complete cure rates forest plot. Overall partial cure rates were reported in 1,703 patients. The overall rate of partial cure following percutaneous sclerotherapy with any agent was 28.0% (95% CI, 22.1--34.0%). Partial cure rates ranged from 16.2% (95% CI, 4.7--27.6%) for pingyangmycin to 35.3% (95% CI, 19.1--51.5%) with ethanol. The overall rate of no benefit following percutaneous sclerotherapy was reported in 1,736 patients and was 4.5% (95% CI, 3.0--6.1%). STS sclerotherapy had the highest rate of no benefit (14.9%; 95% CI, 4.3--25.4%) while pingyangmycin had the lowest rate of no benefit (0.6%; 95% CI, 0.0--1.6%). Patient satisfaction was reported in 315 patients. Overall patient satisfaction rates were 91.0% (95% CI, 86.1--95.9%). Patient satisfaction rates ranged from 72.8% (95% CI, 63.6--81.9%) with STS to 96.0% (95% CI, 92.5--99.6%) with ethanol. Improvement in QoL was reported in 243 patients. Overall QoL improvement was 78.9% (95% CI, 67.0--90.8%) ranging from 46.7% (95% CI, 22.4--71.0%) for STS to 98.1% (95% CI, 94.5--100%) with ethanolamine.

Safety outcomes
---------------

Overall permanent morbidity and mortality rates were reported in 1,303 patients. The overall rate of permanent morbidity and mortality was 0.8% (95% CI, 0.3--1.3%). The lowest rate was reported with STS, and pingamycin (0.5%, 0.8%) and the highest rate reported was with bleomycin (2.2%; 95% CI, 0.0--5.4%). [Fig. 3](#f3-neuroint-2019-00213){ref-type="fig"} shows the permanent morbidity and mortality rates forest plot. Local temporary complication rates were reported in 1,312 patients. The overall rate of local temporary complications was 41.8% (95% CI, 27.0--56.5%). Local temporary complications were highest with ethanolamine (51.0%; 95% CI, 24.7--26.6%) and were lowest with bleomycin (27.0%; 95% CI, 5.4--59.4%). Pulmonary complication rates were reported in 1,222 patients. The overall rate was 0.6% (95% CI, 0.2--1.0%). Pulmonary complication rate was lowest for pingamycin (0.8%; 95% CI, 0.0--2.3%), and was highest for STS (2.4%; 95% CI, 0.5--5.3%). [Fig. 4](#f4-neuroint-2019-00213){ref-type="fig"} shows the pulmonary complication rates forest plot. Skin necrosis and scarring rates were reported in 1,273 patients and the overall rate was 1.5% (95% CI, 0.8--2.1%). Rates were highest with bleomycin (2.3%; 95% CI, 1.0--5.7%) and lowest with pingamycin (0.8%; 95% CI, 0.0--2.3%). [Fig. 5](#f5-neuroint-2019-00213){ref-type="fig"} shows the skin necrosis and scarring rates forest plot. The efficacy and safety outcomes are summarized in [Tables 2](#t2-neuroint-2019-00213){ref-type="table"} and [3](#t3-neuroint-2019-00213){ref-type="table"}.

Study heterogeneity
-------------------

I^2^ values were \>50% indicating substantial heterogeneity for the following outcomes: lack of benefit, improvement in QoL, local temporary complication, overall cure, partial cure, patient satisfaction and systemic side effects. I^2^ values were \<50% indicating lack of substantial heterogeneity for the following outcomes: permanent morbidity and mortality, pulmonary complications and skin necrosis/scarring.

DISCUSSION
==========

Our systematic review and meta-analysis of percutaneous image guided sclerotherapy for treatment of VMs of the head face and neck found that the overall efficacy rate of sclerotherapy was high with complete and partial cure rates of over 90%. Over 90% of patients reported satisfaction with the results of their sclerotherapy treatments and over 70% reported improvements in QoL. Temporary local complication rates were high, however rates of permanent morbidity and mortality as well as permanent scarring were low. When performing subgroup analyses by agent, we found that agents such as ethanol, pingamycin and ethanolamine were generally associated with the highest rates of cure and patient satisfaction, however these agents were also associated with higher rates of local temporary complications. These findings are important as they provide important information regarding the risks and benefits of percutaneous sclerotherapy for VMs of the head, face and neck.

The efficacy of sclerotherapy for VMs is dependent on both the angioarchitecture of the venous malformation, the sclerosing agent used and the dwell time of the sclerosant within the venous malformation \[[@b42-neuroint-2019-00213]\]. Angioarchitecture can be easily assessed on contrast venography following percutaneous injection of the lesion. According to Gemmette et al, the 4 morphological subtypes of VMs are as follows: type I, isolated malformation without discernible venous drainage; type II, lesions draining into normal veins; type III, lesions draining into dysplastic veins; type IV, lesion consists primarily of venous ectasia \[[@b42-neuroint-2019-00213]\]. Types I and II are thought to respond best to sclerotherapy. None of the studies included in our analysis examined outcomes by lesion angioarchitecture, however this undoubtedly is an important factor in determining outcomes.

A summary of the different sclerosing agents is provided in [Table 4](#t4-neuroint-2019-00213){ref-type="table"}. Based on our study, it is clear that sclerosants such as ethanol, ethanolamine oleate and pingyangmycin are generally more effective at inducing a complete or partial cure of the VM. However, this comes at the cost of increased risk of permanent morbidity as well as local side effects. Medications such as ethanol, ethanolamine and pingyangmycin act by directly inducing endothelial injury and thrombosis of the VM \[[@b43-neuroint-2019-00213]\]. Meanwhile, less potent sclerosing agents such as STS and bleomycin work by inducing a nonspecific inflammatory reaction within the VM \[[@b43-neuroint-2019-00213]\]. Adverse side effects of sclerosing agents also differ by agent and are summarized in [Table 4](#t4-neuroint-2019-00213){ref-type="table"}. In brief, adverse side effects are generally most severe with ethanol and include nerve injury, skin necrosis, and cardiopulmonary collapse \[[@b43-neuroint-2019-00213]\]. Side effects are least severe with bleomycin and include mucositis and skin pigmentation.

It is important to point out that a variety of factors should go into the decision regarding which sclerotherapeutic agent to use. Choice of agent should be based on the depth of the venous malformation from the skin surface as well as the ability to limit non-target sclerotherapy and venous thrombosis. Alcohol is generally best used for deeper VMs due to the risk of skin necrosis from extravasation \[[@b4-neuroint-2019-00213],[@b28-neuroint-2019-00213],[@b29-neuroint-2019-00213]\]. Superficial VMs are likely best treated with milder agents such as bleomycin or STS \[[@b5-neuroint-2019-00213],[@b26-neuroint-2019-00213],[@b28-neuroint-2019-00213],[@b29-neuroint-2019-00213]\].

The results from our study compare favorably to other modalities of treatment including medical therapy, surgical resection and laser therapy. Conservative management techniques for VMs are centered around pain control, prevention of phlebitis or thrombosis and prevention of bleeding \[[@b43-neuroint-2019-00213]\]. Pain can generally be managed with anti-inflammatory medications and analgesics. Low dose aspirin can provide pain relief in patients with venous malformation thrombosis \[[@b24-neuroint-2019-00213],[@b31-neuroint-2019-00213]\]. Recently the mammalian target of rapamycin inhibitor sirolismus has been trialed for treatment of VMs and has been found to result in symptom improvement in approximately 80% of patients \[[@b44-neuroint-2019-00213]\]. Surgical excision of VMs is usually part of staged multimodal treatment of VMs \[[@b45-neuroint-2019-00213]\]. However, surgical excision alone is often considered when lesions are smaller and are not adjacent to vital structures. Surgical excision of large invasive VMs is often very challenging due to the presence of poorly defined tissue planes and proximity to important structures. In such cases, intralesional sclerotherapy can be considered as a useful adjunct to surgery as part of an interdisciplinary approach \[[@b46-neuroint-2019-00213]\]. Small case series have reported various levels of efficacy with surface and endovenous/interstitial laser therapy for treatment of VMs, most series report efficacy rates ranging from 70--90%. Combined laser and sclerotherapy treatment has also been shown to be effective as part of an interdisciplinary approach \[[@b46-neuroint-2019-00213]\].

Limitations
-----------

Our study has limitations. This meta-analysis was based primarily off of single-center case series and thus has limitations inherent to single center retrospective studies. There was high risk of bias in 21 series. While we were able to perform subgroup analyses based on sclerotherpeutic agent used, we were unable to perform more granular analyses stratifying outcomes by lesion location. Follow-up in the included studies is limited. Many of our outcomes are subjective and volumetric analyses documenting lesion improvement were not available for a vast majority of the included studies. Nonetheless, our study provides helpful information for both patients and providers who are considering percutaneous sclerotherapy for treatment of VMs and provides guidance for future areas of investigation.

CONCLUSIONS
===========

Our systematic review and meta-analysis of 37 studies and over 2,000 patients found that percutaneous sclerotherapy is a very safe and effective treatment modality for treatment of VMs of the head, neck and face. As expected, mild sclerosing agents such as bleomycin and STS were associated with lower efficacy rates but generally superior safety profiles than stronger sclerosing agents such as ethanol, ethanolamine and pingyangmycin. Further prospective studies are needed to validate our results and determine the optimal treatment strategies for patients with VMs of the head, face and neck.
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![Forest plot: complete cure rates. Subgroup 1, bleomycin; subgroup 2, ethanol; subgroup 3, sotradecol; subgroup 5, mixed/other; subgroup 6, ethanolamine; subgroup 7, pingyangmycin. CI, confidence interval.](neuroint-2019-00213f2){#f2-neuroint-2019-00213}

![Forest plot: permanent morbidity and mortality rates. Subgroup 1, bleomycin; subgroup 2, ethanol; subgroup 3, sotradecol; subgroup 5, mixed/other; subgroup 6, ethanolamine; subgroup 7, pingyangmycin. CI, confidence intervall; EV, number of events; TRT, number of treated patients.](neuroint-2019-00213f3){#f3-neuroint-2019-00213}

![Forest plot: pulmonary complication rates. Subgroup 1, bleomycin; subgroup 2, ethanol; subgroup 3, sotradecol; subgroup 5, mixed/other; subgroup 6, ethanolamine; subgroup 7, pingyangmycin. CI, confidence interval; EV, number of events; TRT, number of treated patients.](neuroint-2019-00213f4){#f4-neuroint-2019-00213}

![Forest plot: skin necrosis and scarring rates. Subgroup 1, bleomycin; subgroup 2, ethanol; subgroup 3, sotradecol; subgroup 5, mixed/other; subgroup 6, ethanolamine; subgroup 7, pingyangmycin. CI, confidence interval; EV, number of events; TRT, number of treated patients.](neuroint-2019-00213f5){#f5-neuroint-2019-00213}

###### 

Summary of studies \[[@b1-neuroint-2019-00213]-[@b37-neuroint-2019-00213]\]

  No.   Study                                                     No. of patients   Mean/median age (years)   M:F       No. of malformations treated   Location of malformations (if specific)                                           Sclerosing agent                                          Mean volume used (mL)        Mean No. of treatment sessions   Mean length of radiographic follow-up (months)   Mean length of clinical follow-up (months)
  ----- --------------------------------------------------------- ----------------- ------------------------- --------- ------------------------------ --------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------- -------------------------------- ------------------------------------------------ --------------------------------------------
  1     Akan et al. \[[@b1-neuroint-2019-00213]\] (2017)          13                30                        1:12      66                             Oropharynx                                                                        Ethanol                                                   6                            1.8                              NR                                               11
  2     Alakailly et al. \[[@b2-neuroint-2019-00213]\] (2015)     13                18.2                      1:3.3     14                             NR                                                                                STS                                                       NR                           1.4                              9                                                9
  3     Alexander et al. \[[@b3-neuroint-2019-00213]\] (2016)     37                21.7                      14:23     37                             NR                                                                                STS, ethanolamine                                         NR                           1.5                              20.8                                             20.8
  4     Baek et al. \[[@b4-neuroint-2019-00213]\] (2011)          22                30.3                      1:1.2     NR                             NR                                                                                Ethanol                                                   8.5                          1.7                              NR                                               13
  5     Bajpai and Bajpai \[[@b5-neuroint-2019-00213]\] (2012)    8                 17                        1:1       NR                             NR                                                                                Bleomycin                                                 NR                           1.1                              12                                               30
  6     Bajpai and Bajpai \[[@b5-neuroint-2019-00213]\] (2012)    8                 15                        1:1       NR                             NR                                                                                STS                                                       NR                           5                                NR                                               30
  7     Bourgouin et al. \[[@b6-neuroint-2019-00213]\] (2018)     33                43                        1:1       46                             Oropharynx                                                                        STS                                                       NR                           2.9                              9                                                3
  8     Castren et al. \[[@b7-neuroint-2019-00213]\] (2016)       75                35.9                      1:1.2     75                             NR                                                                                STS, polidocanol, bleomycin, ethanol doxycyclin           NR                           2                                NR                                               18
  9     Chen et al. \[[@b8-neuroint-2019-00213]\] (2015)          11                36                        1:1       NR                             NR                                                                                NR                                                        21                           4                                                                                 6
  10    Chen et al. \[[@b9-neuroint-2019-00213]\] (2010)          18                11.8                      1:1.25    NR                             Face, neck                                                                        OK-432 , PYM                                              NR                           NR                               NR                                               8.4
  11    Chen et al. \[[@b10-neuroint-2019-00213]\] (2008)         19                15                        1:1       NR                             Orbital                                                                           PYM                                                       NR                           NR                               23                                               23
  12    Choi et al. \[[@b11-neuroint-2019-00213]\] (2002)         29                22                        10:19     29                             Cheek, lip, submandibular, temporalis muscle, scalp, parotid, orbit, oropharynx   Ethanolamine                                              NR                           2                                8.5                                              8.5
  13    Colletti et al. \[[@b12-neuroint-2019-00213]\] (2017)     69                34                        NR        69                             NR                                                                                STS                                                       7.75                         2.1                              NR                                               NR
  14    Costa et al. \[[@b13-neuroint-2019-00213]\] (2011)        53                51.5                      1:1.2     66                             Oral, maxillofacial                                                               Ethanolamine                                              NR                           1                                                                                 
  15    Jia et al. \[[@b14-neuroint-2019-00213]\] (2014)          33                23.8                      15:18     33                             Orbital, periorbital                                                              PYM                                                       NR                           2                                7.9                                              7.9
  16    Kim et al. \[[@b15-neuroint-2019-00213]\] (2004)          10                5.4                       1:1.5     NR                             NR                                                                                Bleomycin                                                 NR                           4.3                              NR                                               NR
  17    Kim et al. \[[@b15-neuroint-2019-00213]\] (2004)          35                21                        1:1       NR                             NR                                                                                OK-432                                                    8.5                          1.8                              NR                                               11
  18    Kim et al. \[[@b15-neuroint-2019-00213]\] (2004)          29                22                        1:1.9     NR                             NR                                                                                Ethanolamine                                              NR                           NR                               NR                                               NR
  19    Kishi et al. \[[@b16-neuroint-2019-00213]\] (2014)        23                32                        1:1.5     35                             NR                                                                                Ethanol                                                   NR                           NR                                                                                
  20    Lamba et al. \[[@b17-neuroint-2019-00213]\] (2012)        15                25                        10:5      15                             Face, neck                                                                        Ethanol                                                   21                           1.2                              7.6                                              7.6
  21    Lee et al. \[[@b18-neuroint-2019-00213]\] (2009)          87                17.5                      40:47     NR                             NR                                                                                Ethanol                                                   38                           3.5                              35                                               35
  22    Li et al. \[[@b19-neuroint-2019-00213]\] (2010)           20                17.14                     10:10     21                             Maxillofacial                                                                     PYM, Ethanol                                              18,9 (PYM), 12.5 (ethanol)   2.4                              13.5                                             13.5
  23    Liu et al. \[[@b20-neuroint-2019-00213]\] (2009)          23                21                        12:11     23                             Cheek, parotid, infraorbital, scalp, chin, submandibular, oral                    PYM, Ethanol                                              22 (PYM), 2.8 (ethanol)      2.5                              2.5                                              20.3
  24    Meng et al. \[[@b21-neuroint-2019-00213]\] (2014)         43                20.5                      26:17     43                             Tongue, pharynx, parotid                                                          PYM, Ethanol                                              NR                           NR                               24                                               24
  25    Orlando et al. \[[@b22-neuroint-2019-00213]\] (2014)      51                23                        14:37     51                             Face, tongue, neck, lip                                                           Ethanol                                                   2.5                          7                                18                                               18
  26    Ribeiro et al. \[[@b23-neuroint-2019-00213]\] (2018)      17                41.6                      6:11      34                             NR                                                                                Ethanolamine                                              NR                           2.8                              6                                                6
  27    Rosbe et al. \[[@b24-neuroint-2019-00213]\] (2010)        10                20.3                      4:06      12                             Masseter                                                                          STS                                                       NR                           1                                28                                               28
  28    Sachin et al. \[[@b25-neuroint-2019-00213]\] (2013)       358               NR                        NR        358                            NR                                                                                Butyl cyanoacrylate, polyvinyl alcohol, STS, bleomycine   NR                           NR                               4.7                                              56.4
  29    Shigematsu et al. \[[@b26-neuroint-2019-00213]\] (2019)   18                34.3                      6:12      18                             Eyes                                                                              Bleomycin                                                 34.5                         3                                43                                               43
  30    Siniluoto et al. \[[@b27-neuroint-2019-00213]\] (1997)    34                28                        14.24     34                             NR                                                                                STS                                                       11.8                         2.2                              NR                                               nr
  31    Songsaeng et al. \[[@b28-neuroint-2019-00213]\] (2015)    33                25.1                      6:27      43                             NR                                                                                Bleomycin, ethanol                                        NR                           3                                14.7                                             14.7
  32    Spence et al. \[[@b29-neuroint-2019-00213]\] (2011)       17                40                        7:09      17                             Face, tongue, parotid                                                             Ethanol                                                   8.1                          1.7                              6                                                6
  33    Spence et al. \[[@b29-neuroint-2019-00213]\] (2011)       17                32.4                      5:12      17                             Face, tongue, parotid                                                             Bleomicyn                                                 NR                           3.4                              6                                                6
  34    Spence et al. \[[@b30-neuroint-2019-00213]\] (2010)       31                34.4                      14:17     32                             Face, orbital, parotid, oropharinx                                                Bleomicyn                                                 NR                           3.5                              5.2                                              5.2
  35    Stimpson et al. \[[@b31-neuroint-2019-00213]\] (2012)     12                7                         7:05      12                             Oropharynx                                                                        STS                                                       NR                           3                                28                                               28
  36    Su et al. \[[@b32-neuroint-2019-00213]\] (2010)           60                22.6                      26:34     60                             Face, neck                                                                        Ethanol                                                   11.2                         1.8                              8                                                8
  37    Wang et al. \[[@b33-neuroint-2019-00213]\] (2017)         21                25.4                      12:09     72                             Oropharynx, head, neck                                                            Ethanol                                                   79.6                         1.5                              9.1                                              9.1
  38    Wang et al. \[[@b34-neuroint-2019-00213]\] (2010)         23                19                        13:10     23                             Parotid, oral, neck, face                                                         Ethanol                                                   73                           1.5                              25                                               25
  39    Zhao et al. \[[@b35-neuroint-2019-00213]\] (2004)         260               NR                        131:159   260                            Oral, face                                                                        PYM, sodium morrhuate                                     NR                           1.7                              NR                                               NR
  40    Zheng et al. \[[@b36-neuroint-2019-00213]\] (2009)        297               20.6                      159:138   297                            Oral, maxillofacial, head, neck                                                   PYM                                                       NR                           3.5                              36                                               36
  41    Zhi et al. \[[@b37-neuroint-2019-00213]\] (2008)          82                12                        26:56     82                             Maxillofacial                                                                     PYM                                                       NR                           2.9                              24                                               24

No., number; M, male; F, female; NR, not reported; STS, sodium tetradecyl sulfate; PYM, pingyangmycin.

###### 

Summary of overall outcomes

                                      Overall (%) (95% CI)
  ----------------------------------- ----------------------
  Complete cure                       64.7 (57.4--72.0)
  Partial cure                        28.0 (22.1--34.0)
  No benefit                          4.5 (3.0--6.1)
  Improvement in QoL                  78.9 (67.0--90.8)
  Patient satisfaction                91.0 (86.1--95.9)
  Pulmonary complication              0.6 (0.2--1.0)
  Skin necrosis/scar                  1.5 (0.8--2.1)
  Any permanent morbidity/mortality   0.8 (0.3--1.3)
  Local temporary complication        41.8 (27.0--56.5)

QoL, quality of life; CI, confidence interval.

###### 

Summary of outcomes by agents

                                      Bleomycin            Ethanol   Sodium tetradecyl sulfate   Ethanolamine   Pingamycin                                                                       
  ----------------------------------- -------------------- --------- --------------------------- -------------- -------------------- --------- ------------------- --------- ------------------- ---------
  Complete cure                       66.1 (31.3--100.9)   Ref.      58.8 (39.8--77.9)           0.004          55.5 (36.1--74.9 )   0.005     78.3 (58.9--97.6)   \<0.001   85.9 (72.7--99.2)   \<0.001
  Partial cure                        24.5 (1.7--47.3)     Ref.      35.3 (19.1--51.5)           0.18           25.9 (13.1--38.6)    0.08      19.5 (2.1--37.0)    0.05      12.5 (1.0--24.0)    0.03
  No benefit                          12.9 (0.7--26.6)     Ref.      4.0 (1.2--6.8)              0.003          14.9 (4.3--25.4)     0.02      2.1 (0.2--4.4)      \<0.001   2.6 (0.1--5.2)      \<0.001
  Improvement in QoL                                       Ref.      89.8 (76.4--3.2)                           46.7 (22.4--71.0)              98.1 (94.5--100)                                  
  Patient satisfaction                94.3 (88.3--100.3)   Ref.      96.0 (92.5--99.6)           0.72           72.8 (63.6--81.9)    \<0.001   76.5 (62.2--90.7)   0.02                          
  Pulmonary complication              2.2 (0.0--5.4)       Ref.      1.5 (0.2--2.8)              1.00           2.4 (0.5--5.3)       0.38      2.0 (0.0--5.9)      1.00      0.8 (0.0--2.3)      1.00
  Skin necrosis/scar                  2.3 (1.0--5.7)       Ref.      1.4 (0.1--2.7)              0.69           2.1 (0.8--3.4)       0.71      2.0 (0.0--5.9)      1.00      0.8 (0.0--2.3)      0.35
  Any permanent morbidity/mortality   2.2 (0.0--5.4)       Ref.      1.0 (0.1--2.1)              1.00           0.5 (0.1--1.2)       1.00      1.8 (0.0--4.8)      1.00      0.8 (0.0--2.3)      1.00
  Local temporary complication        27.0 (5.4--59.4)     Ref.      30.0 (3.3--56.7)            0.61           44.0 (10.6--77.4)    \<0.001   51.0 (24.7--26.6)   \<0.001   36.2 (19.7--92.1)   0.45

CI, confidence interval; Ref., reference; QoL, quality of life.

###### 

Summary of commonly used agents

  Agent                       Mechanism of action                                                                    Standard dose                                  Adverse effects
  --------------------------- -------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------
  Ethanol                     Endothelial denudation and thrombosis                                                  1 mL/kg, most studies have max of 10--20 mL    Skin necrosis, tachycardia, DVT, PE, pain
  Bleomycin                   DNA damage. Lipid peroxidation, non-specific inflammatory reaction                     1 mg/kg up to 15 mg                            Skin pigmentation, fever, mucositis, pulmonary toxicity (rare)
  Sodium tetradecyl sulfate   Detergent resulting in lipid damage in vessel wall, inflammatory reaction              0.5--2 mL of 3% solution                       Pain, edema, ecchymosis, nerve injury
  Ethanolamine oleate         Fatty acid emulsion inducing endothelial damage and thrombosis                         2 mL of 50 mg/mL solution                      Skin ulceration and necrosis
  Pingyangmycin               DNA damage. Lipid peroxidation, non-specific inflammatory reaction                     8 mg in a 2 mg/mL solution                     Atrophy of subcutaneous tissues, fever, swelling, anaphylactic shock
  OK-432                      Natural killer cell activator resulting in inflammation and endothelial permeability   0.1 mg dried cocci in 10 mL of normal saline   Fever, pain, edema, inflammation
  Doxycycline                 Inhibition of matrix metalloproteins and VEGF \> decreased angiogenesis                10--20 mg/kg                                   Severe pain on injection

DVT, deep vein thrombosis; PE, pulmonary embolism; VEGF, vascular endothelial growth factor.
